Market Size
The global cutaneous and systemic leishmaniasis market size is valued at US$372.4 million in 2025 and is projected to reach US$470.5 million by 2033, growing at a CAGR of 3.0% during the forecast period from 2025 to 2033.
Cutaneous leishmaniasis is also known as oriental sore, tropical sore, Aleppo boil, Delhi Boil, or desert boil. It is the most common form of leishmaniasis affecting humans. The cutaneous form presents with skin ulcers. It is a skin infection caused by a single-celled parasite that is transmitted by the bite of a phlebotomine sandfly. There are about twenty species of Leishmania that cause cutaneous leishmaniasis.
Market Dynamics
Research and development by prominent manufacturers of this market to introduce new drugs into the market, which are more effective as well as affordable is the key factor driving the global cutaneous and systemic leishmaniasis market. In addition, undergoing clinical trials, which are likely to receive regulatory approval along with increasing government spending on healthcare infrastructure is also estimated to boost the cutaneous & systemic leishmaniasis market. Rising prevalence of cutaneous & systemic leishmaniasis is expected to propel market growth. According to WHO (World Health Organization), around 700,000 to 1 million new cases and some 26,000 to 65,000 deaths occur annually due to cutaneous and systemic leishmaniasis.
However, the treatment for cutaneous and systemic leishmaniasis is very expensive and can cause serious adverse effects such as vomiting, nausea, anorexia, myalgia, abdominal pain, headache, arthralgia, and lethargy and can rarely cause the severe reaction of fatal cardiac arrhythmia. Also, the WHO considers leishmaniasis as one of the main neglected diseases in the world. All these factors are hampering the global cutaneous and systemic leishmaniasis market growth.
Market Segmentation
Based on the indication the global Cutaneous and Systemic Leishmaniasis market is broadly segmented as cutaneous leishmaniasis, mucosal leishmaniasis, and visceral leishmaniasis. Due to increasing incidences of visceral leishmaniasis. Visceral leishmaniasis (VL) is characterized by recurrent bouts of fever, weight loss, enlargement of the spleen and liver, and anemia. According to WHO (World Health Organization), most cases occur in Brazil, East Africa, and South-East Asia, and approximately 50 000 to 90 000 new cases of VL occur worldwide every year.
Market Geographical Share
The global Cutaneous and Systemic Leishmaniasis market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. It is owing to the high incidence rate of cutaneous & systemic leishmaniasis, in these regions. With a high percentage of disease incidence annually, the demand for drug-based products is estimated to grow significantly. Approximately 75% of cutaneous leishmaniasis is majorly reported in Afghanistan, Algeria, Brazil, Colombia, Costa Rica, Ethiopia, Islamic Republic of Iran, North Sudan, Peru, and the Syrian Arab Republic. Brazil represents approximately 90% of the VL cases in the Latin America region.
Market Key Players
Significant players of the global cutaneous and systemic leishmaniasis market are GlaxoSmithKline Plc.; Gilead Sciences, Inc.; Profounda Pharmaceuticals; Knight Therapeutics Inc.; Janssen Global Services, LLC; Albert David Ltd; Jubilant Life Sciences Ltd; Novartis AG; Sanofi A.G; Bristol-Myers Squibb Company, and others. Majority of these prominent players are adopting a few organic and inorganic strategies such as product launches, collaboration, and product agreements, and other key developments to enhance their product portfolio in the global cutaneous and systemic leishmaniasis market.
Recent Development-
- December 2025: Gilead Sciences continued supply expansion of liposomal amphotericin B (AmBisome) through global access programs, strengthening partnerships with the World Health Organization to improve treatment availability for visceral leishmaniasis in endemic regions.
- November 2025: World Health Organization and regional health ministries in South Asia scaled up elimination programs for visceral leishmaniasis (kala-azar), reporting intensified use of single-dose liposomal amphotericin B treatment protocols across India, Bangladesh, and Nepal.
- October 2025: Drugs for Neglected Diseases initiative expanded clinical trial sites in India for new oral drug combinations targeting both visceral and post-kala-azar dermal leishmaniasis (PKDL), aiming to simplify outpatient treatment.
- October 2025: Drugs for Neglected Diseases initiative, in collaboration with U.S.-based research partners, advanced clinical evaluation of oral combination therapies for visceral leishmaniasis, focusing on shorter-duration and safer regimens to replace toxic antimonial treatments.
